Selective antagonism of cJun for cancer therapy

Area of Science:

• Molecular Biology
• Cancer Research
• Biochemistry

Background:

• The activator protein-1 (AP-1) family of transcription factors regulates cellular signaling pathways with both oncogenic and anti-oncogenic potential.
• AP-1's function is dictated by its dimeric composition and cellular context, influencing gene transcription.
• Aberrant AP-1 activity is implicated in various cancers.

Purpose of the Study:

• To investigate the specific role of cJun, a key member of the AP-1 family, in the development and progression of diverse cancers.
• To explore the potential of targeting cJun as a therapeutic strategy in oncology.
• To review and categorize small molecules and peptides designed to inhibit cJun activity.

Main Methods:

• Correlative studies analyzing cJun protein levels in patient tumor samples.
• Mechanistic investigations using cancer cell models to elucidate cJun's role in cancer signaling.
• Literature review and categorization of small molecules and peptides targeting the cJun-DNA complex.

Main Results:

• Evidence linking cJun to a range of cancers through both correlative and mechanistic studies.
• Identification of cJun as a central node in cancer-altered signaling pathways.
• Summary of therapeutic agents targeting specific binding surfaces of the cJun-DNA complex.

Conclusions:

• cJun is a significant focal point in cancer-altered signaling with potential for therapeutic intervention.
• Selective antagonism of oncogenic cJun functions, while avoiding interference with anti-oncogenic roles, is crucial for effective cancer therapy.
• Development of targeted small molecules and peptides offers promising avenues for cJun-based cancer treatments.